Ann: Investor Presentation, page-5

So far, the total (placebo group + two treatment groups) have 70% reduction at 12 weeks. Assume placebo group achieves 55% reduction at 12 weeks, as per graph. Assume also that both treatment groups have same wound reduction. Simple algebra shows that reduction to be 77%. Thus the treatment over standard care delivers 22% greater wound reduction - much better than "pretty effective".

The study design has primary endpoint efficacy success at 10% greater reduction for treatment over standard care (i.e., ~70% VF001 and ~60% placebo). But so far it looks like it might achieve 22%. So, even before the results are unblinded there is a very strong indication that this will be a success.